{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"TRIM-EBC","nct_id":"NCT06517212","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trim-ebc-nct06517212. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TRIM-EBC","arms":[{"description":"Patients will be treated with tirzepatide 15mg subcutaneously (SC) weekly (starting with 2.5mg SC weekly and increasing by 2.5mg monthly over 6 months) and will be monitored closely for tolerability, safety, and weight loss. Patients may be treated with tirzepatide for up to 2 years on trial if they remain without evidence of metastatic disease recurrence and provided there's demonstrated safety of tirzepatide with associated weight loss.","label":"tirzepatide","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-12-31","type":"ESTIMATED"},"conditions":["Breast Cancer","Breast Neoplasms","Breast Cancers"],"enrollment":{"count":48,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Tirzepatide","otherNames":["ZepBound"],"type":"DRUG"}],"last_update":"2026-02-12","lead_sponsor":"Baylor Research Institute","official_title":"Adjuvant Tirzepatide Plus Standard of Care Endocrine Therapy in Patients With Obesity or Overweight Who Have Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, With Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"ctDNA efficacy","timeFrame":"2 years"},{"measure":"distant disease-free survival efficacy","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2024-11-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tirzepatide Weight Loss for MRD+ Early Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06517212"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trim-ebc-nct06517212"}